Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore cutting-edge research on tumor-reactive T cells in non-small cell lung cancer through this 41-minute keynote presentation by Dr. Kellie Smith from Johns Hopkins School of Medicine. Learn about innovative methods being developed to detect and study tumor-infiltrating lymphocytes (TIL) in resectable lung cancers, with a focus on distinguishing true tumor-specific T cells from those with irrelevant antigen specificity. Discover how neoadjuvant PD-1 blockade combined with chemotherapy has become the standard of care for early-stage NSCLC patients, and understand the critical role of CD4+ helper and CD8+ effector T cells in targeting neoantigens derived from tumor somatic mutations. Gain insights into the phenotype, function, and spatial interactions of tumor-reactive TIL, addressing fundamental limitations in current single-cell analysis studies of intratumoral T cell characteristics in human cancers. The presentation covers Dr. Smith's collaborative work on immunotherapy clinical trials aimed at improving treatment options, preventing disease recurrence, and identifying predictors of response to treatment in both early and advanced stage disease.
